Should You Buy Burning Rock Biotech Limited Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Burning Rock Biotech Limited (BNR) occupies a solid middle-ground position with a Quality of Company score of 6.5/10. At the current market price of $11.68, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.
The short answer: 0 of 1 CirclFi valuation models project upside for Burning Rock Biotech Limited (BNR) at $11.68 — the model consensus leans bearish, with a Quality Score of 6.5/10 and Value-Trap risk of 31/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Burning Rock Biotech Limited (BNR) in 2026?
What Is the Bull Case vs the Bear Case for Burning Rock Biotech Limited (BNR)?
| Bull case | Bear case — $10.94 target (-6.3%) |
|---|---|
| No active model projects meaningful upside for BNR at $11.68. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. | Industry headwind: generic/biosimilar competition represents a meaningful risk for Burning Rock Biotech Limited and its Diagnostics & Research peers. |
How Does BNR Compare to Its Diagnostics & Research Peers?
Valuation data pages: MYGN · WGS · NEO · AWHL · RDNT · PSNL · ISPC · VCYT · RVTY · IDXX · MEDP
Which Other Stocks Score Like BNR on Quality?
Closest companies to BNR’s Quality of Company score of 6.5/10, across all industries.
- KRMD — KORU Medical Systems, Inc. (QOC 6.5) · analysis
- IMCR — Immunocore Holdings plc (QOC 6.5) · analysis
- VRDN — Viridian Therapeutics, Inc. (QOC 6.5) · analysis
- KYMR — Kymera Therapeutics, Inc. (QOC 6.5) · analysis
- TCI — Transcontinental Realty Investors, Inc. (QOC 6.5) · analysis
- ZH — Zhihu Inc. (QOC 6.4) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
So Is Burning Rock Biotech Limited (BNR) Worth Buying in 2026?
Our valuation engine sends a clear cautionary signal on Burning Rock Biotech Limited at $11.68. 1/1 models flag overvaluation, median fair value sits at $10.94 (-6.3%), and the risk-reward profile appears unfavorable. Quality at 6.5/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. Burning Rock Biotech Limited's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About BNR Stock?
Should I buy BNR stock right now?
Based on CirclFi's multi-model analysis, 0 of 1 models see upside for BNR at $11.68. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Burning Rock Biotech Limited?
Key risks include: limited model coverage (1/13 active), reducing analytical confidence; general market and sector-specific risks affecting Diagnostics & Research companies. Always diversify and consult a financial advisor.
How does BNR compare to its competitors?
Among Diagnostics & Research peers, BNR holds a Quality Score of 6.5/10. Comparable companies include MYGN (QOC 6.6), WGS (QOC 6.4), NEO (QOC 6.6). The relative ranking helps investors identify whether BNR offers better fundamental quality than alternatives in the same sector.
Is BNR a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. BNR's Quality Score of 6.5/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy BNR at?
CirclFi does not provide target buy prices or price alerts. However, our 1 active models produce fair value estimates ranging from $10.94 to $10.94. At $11.68, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for BNR.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad